All-cause mortality in young women with endometrial cancer receiving progesterone therapy.

ABSTRACT:

Background

Uterine-preserving therapy with progesterone may be used in young women with endometrial cancer who desire fertility preservation. Such therapy delays definitive treatment with hysterectomy.

Objective

We examined the use and safety of progestational therapy in young women with endometrial cancer. The primary outcome of the analysis was overall survival.

Study design

We identified women ≤49 years of age with stage I endometrial cancer in the National Cancer Database from 2004 through 2014. Women treated with hormonal therapy with or without hysterectomy were compared to women treated with hysterectomy. After propensity score weighting, overall survival was examined using proportional hazards models.

Results

A total of 23,231 patients, including 872 (3

SUBMITTER: Ruiz MP 

PROVIDER: S-EPMC5712259 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature